Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down – Here’s What Happened

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $7.09, but opened at $6.27. Gyre Therapeutics shares last traded at $5.6240, with a volume of 25,692 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Gyre Therapeutics has an average rating of “Reduce”.

Check Out Our Latest Stock Analysis on Gyre Therapeutics

Gyre Therapeutics Stock Performance

The firm has a market cap of $564.24 million, a PE ratio of -24.16 and a beta of 1.89. The stock has a 50-day simple moving average of $6.78 and a two-hundred day simple moving average of $7.00.

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $29.11 million during the quarter, compared to the consensus estimate of $26.49 million. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. As a group, sell-side analysts anticipate that Gyre Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Gyre Therapeutics

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Gyre Therapeutics in the 2nd quarter worth approximately $6,550,000. Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the second quarter valued at approximately $414,000. Deutsche Bank AG purchased a new stake in Gyre Therapeutics during the second quarter valued at approximately $118,000. Dimensional Fund Advisors LP raised its position in Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after acquiring an additional 14,365 shares during the period. Finally, Bank of America Corp DE purchased a new position in shares of Gyre Therapeutics during the 2nd quarter worth $83,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.

See Also

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.